

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, February 5th, 2026
1:05 PM - 4:15 PM
Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Samara Stevens, ND; Bridget Bradley, PharmD; Douglas Carr, MD; Jennifer Henderson, DO; Russ Huffman, PMHNP; Eddie Saito, PharmD; Jeanne Savage, MD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Trevor Douglass, DC; Lan Starkweather, PharmD; Brandon Wells

Audience: Kyle Knudsen, Axsome Therapeutics; Kat Khachatourian, Novo Nordisk; Gene Kelly, Stealth BioTherapeutics; Miranda Ryzenman, Artia Solutions; Holly Jo Hodges, EOCCO/Moda Health; Andy Berg, Concis Labs; Gil Clifton, Stealth Bio; Gary Parenteau, Dexcom; Lee Stout, Chiesi; Jessica Garrison, Gainwell Technologies; Melissa Snider, Gilead; Norm Navarro, Providence; Becky Caswell, OHSU Health Services PBM; Bill McDougall, Biogen; Rosalie Elliott, UHA; Vivian Ton, UHA; Nirmal Ghuman, J&J; Chris Ferrin, IHN; Jennifer Davis, Gilead; Tammi Ocumpaugh, Otsuka; Rachel Peterson, PNWBD; Mariam Alboustani, Dyne Therapeutics; Aliethia McLeod, Trillium; Paul Thompson, Alkermes; Suzanne Morgan; Mark Kantor, AllCare; Lynda Finch, Biogen; Jill Carroll, BMS; William Lam; Daria Meleshkina, Moda EOCCO; Don Robinson, TN; Lewis Backus, OHA; Chris Demars, OHA; Leif Bruce, Novo Nordisk; Bill Branch; Cari Hall, Merck; Gloria Zepeda, AllCare; Dale Fisher, US; Ron Abraham; Brett Freund; Erin Nowak, AbbVie; Kate Landes; Melissa Vultaggio; Randy McCoy, Stealth Bio; Keith Boesen

(*) Provided verbal testimony

I. CALL TO ORDER

- A. Roll Call & Introductions
 - Called to order at approx. 1:05 p.m., introductions by Committee and staff
- B. Conflict of Interest Declaration – no new conflicts of interest were declared
- C. Election of Chair and Vice Chair
 - Dr. Ramirez volunteered to serve as Chair and Dr. Stevens as Vice-Chair**
 - ACTION: Motion to approve, 2nd, all in favor**
- D. Approval of Agenda and December 2025 Minutes presented by Roger Citron, RPh



ACTION: Motion to approve, 2nd, all in favor and Dr. Henderson abstained

- E. Department Update: Andrew Gibler, PharmD
- F. Mental Health Clinical Advisory Group Update: Andrew Gibler, PharmD

II. CONSENT AGENDA TOPICS

A. Oncology Prior Authorization (PA) Updates

Recommendation:

- Add Hyrnuo (sevabertinib) and Komzifti (ziftomenib) to Table 1 in the Oncology Agents PA criteria

B. Orphan Drug Policy Updates

Recommendation:

- Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Myqorzo (aficamten), Jascayd (nerandomilast), and Palsonify (paltusotine) based on their FDA-approved label

ACTION: Motion to approve, 2nd, all in favor

III. DRUG USE REVIEW (DUR) ACTIVITIES

A. Quarterly Utilization Report: Roger Citron, RPh

B. ProDUR Report: Lan Starkweather, PharmD

C. RetroDUR Report: Dave Engen, PharmD

D. Oregon State Drug Review: Kathy Sentena, PharmD

1. New Therapies for Treatment of Chronic Obstructive Pulmonary Disease

2. New Drugs for the Treatment of Uncomplicated Urinary Tract Infections

3. 2025 American College of Cardiology/American Heart Association Joint Committee Clinical Practice Guideline Update

IV. NEW BUSINESS

A. Antidepressant Class Update: Kathy Sentena, PharmD

Recommendations:

- No changes to the PDL are recommended based on review of the evidence
- Update PA criteria to allow for coverage of evidence supported indications for milnacipran
- Add at least one formulation of lithium and bupirone to the PDL to facilitate access to a 100-day supply
- Evaluate comparative costs in executive session

Public Comment: Kyle Knudsen, Axsome Therapeutics

ACTION: Motion to approve, 2nd, all in favor

B. Tryngolza (Olezarsen) New Drug Evaluation: Megan Herink, PharmD

Recommendations:

- Make olezarsen non-preferred in the "Other Dyslipidemia Drug" PDL class



- Implement **APOLIPOPROTEIN C-III (APOC3) Inhibitors** PA criteria to ensure appropriate use
ACTION: Modify proposed PA criteria to allow prescribing by or in consultation with a specialist for non-FCS indication, and define recent labs to be within past 6 months
Motion to approve, 2nd, all in favor

C. Wegovy (semaglutide) Prior Authorization for MASH: Sara Fletcher, PharmD

Recommendations:

- Update PA criteria for Wegovy (semaglutide)
- Evaluate comparative costs in executive session

Public Comment: Kat Khachatourian, Novo Nordisk

ACTION: Motion to approve, 2nd, all in favor

D. Sedatives for Insomnia Class Update: David Engen, PharmD

Recommendations:

- Remove PA for preferred products when there is no history of an opioid or sedative agent to allow for short-term use of up to 4 weeks
- Designate one sedative agent that is not from the benzodiazepine or GABA-A receptor agonist class as preferred
- Evaluate comparative costs in executive session

ACTION: Add BBT-I as an option for access

Motion to approve, 2nd, all in favor

E. Medications for Allergies: Deanna Moretz, PharmD

Recommendations:

- No changes to the PDL are recommended based on review of the evidence
- Create a PDL class for the **first-generation oral antihistamines**
- Remove PA for preferred nasal inhalers in adults
- Create a new PDL class, "**Ophthalmic Medications for Allergies**"
- Make at least one product preferred without prior authorization
- Evaluate comparative costs in executive session

ACTION: Motion to approve, 2nd, all in favor

F. Forzinity (elamipretide) Abbreviated New Drug Evaluation: Sarah Servid, PharmD


Recommendations:

- Implement proposed **Elamipretide** PA to require documentation of genetic testing and supportive care for heart failure

ACTION: Motion to approve, 2nd, all in favor

IV. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; Samara Stevens, ND; Douglas Carr, MD; Jennifer Henderson, DO; Russ Huffman, PMHNP; Eddie Saito, PharmD



Staff Present: Roger Citron, RPh; Sarah Servid, PharmD; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Brandon Wells

V. RECONVENE for PUBLIC RECOMMENDATIONS

A. Antidepressant Class

Recommendation: Make venlafaxine tablets ER 24 hours preferred; make lithium carbonate capsules, tablets and tablet ER preferred; make buspirone tablets preferred; and make lithium citrate solution, Lithobid, and Bucapsol voluntary non-preferred

ACTION: Motion to approve, 2nd, all in favor

B. Wegovy® (semaglutide) for MASH

Recommendations: Remove Ozempic step through for Wegovy for patients who do not have diabetes

ACTION: Motion to approve, 2nd, all in favor

C. Sedatives for Insomnia Class

Recommendations: Make Belsomra (suvorexant) preferred

ACTION: Motion to approve, 2nd, all in favor

D. Medications for Allergies

Recommendations: Make generic oral hydroxyzine pamoate capsules, hydroxyzine tablets, cyproheptadine tablets, diphenhydramine tablets, diphenhydramine capsules, chlorpheniramine tablets, diphenhydramine liquid, and cyproheptadine syrup preferred and all other first generation oral antihistamines non-preferred; make levocetirizine, desloratadine, and fexofenadine tablets and cetirizine solution preferred; make azelastine nasal allergy inhaler preferred; make cromolyn, azelastine, and olopatadine legend ophthalmic drops preferred and all other ophthalmic products nonpreferred

ACTION: Motion to approve, 2nd, all in favor

VI. ADJOURN – Meeting concluded at approximately 4:20 p.m.